Imagion Biosystems Limited
Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, … Read more
Imagion Biosystems Limited (IBXXF) - Total Assets
Latest total assets as of June 2025: $932.48K USD
Based on the latest financial reports, Imagion Biosystems Limited (IBXXF) holds total assets worth $932.48K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Imagion Biosystems Limited - Total Assets Trend (2014–2024)
This chart illustrates how Imagion Biosystems Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Imagion Biosystems Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Imagion Biosystems Limited's total assets of $932.48K consist of 99.4% current assets and 0.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.3% |
| Accounts Receivable | $886.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Imagion Biosystems Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Imagion Biosystems Limited's current assets represent 99.4% of total assets in 2024, an increase from 48.0% in 2014.
- Cash Position: Cash and equivalents constituted 95.3% of total assets in 2024, up from 48.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Imagion Biosystems Limited Competitors by Total Assets
Key competitors of Imagion Biosystems Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Imagion Biosystems Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Imagion Biosystems Limited generates 0.95x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Imagion Biosystems Limited is currently not profitable relative to its asset base.
Imagion Biosystems Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.19 | 0.09 | 2.68 |
| Quick Ratio | 0.19 | 0.09 | 2.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.88 Million | $ -5.29 Million | $ 2.94 Million |
Imagion Biosystems Limited - Advanced Valuation Insights
This section examines the relationship between Imagion Biosystems Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.46 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | -38.9% |
| Total Assets | $2.80 Million |
| Market Capitalization | $1.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Imagion Biosystems Limited's assets below their book value (0.62 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Imagion Biosystems Limited's assets decreased by 38.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Imagion Biosystems Limited (2014–2024)
The table below shows the annual total assets of Imagion Biosystems Limited from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.80 Million | -38.87% |
| 2023-12-31 | $4.59 Million | -54.03% |
| 2022-12-31 | $9.98 Million | -29.33% |
| 2021-12-31 | $14.12 Million | -0.03% |
| 2020-12-31 | $14.12 Million | +189.79% |
| 2019-12-31 | $4.87 Million | -6.08% |
| 2018-12-31 | $5.19 Million | -32.11% |
| 2017-12-31 | $7.64 Million | -37.07% |
| 2016-12-31 | $12.14 Million | +1440.45% |
| 2015-12-31 | $788.19K | +132.84% |
| 2014-12-31 | $338.51K | -- |